TerminatedEarly Phase 1NCT01466855
A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma
Studying Hereditary retinoblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Hospital Medical Center, Cincinnati
- Principal Investigator
- James Geller, MDChildren's Hospital Medical Center, Cincinnati
- Intervention
- Intra-Ophthalmic Artery Topotecan Infusion(drug)
- Enrollment
- 36 enrolled
- Eligibility
- 15 years · All sexes
- Timeline
- 2011 – 2015
Study locations (1)
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01466855 on ClinicalTrials.govOther trials for Hereditary retinoblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06725173Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.University of Washington
- RECRUITINGEARLY PHASE1NCT06972602High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous SeedEye & ENT Hospital of Fudan University
- RECRUITINGPHASE2NCT06679634Retinoblastoma Phase II Expanded Access Clinical TrialTargeted Therapy Technologies, LLC
- RECRUITINGEARLY PHASE1NCT06424301Targeting NUDT21 siRNA Drugs for Patients With Refractory RetinoblastomaEye & ENT Hospital of Fudan University
- RECRUITINGNCT06367530Trilateral Retinoblastoma: Incidence and OutcomesAmsterdam UMC, location VUmc
- ENROLLING BY INVITATIONNCT06227962Cognitive Functioning and Health Related Quality of Life in Retinoblastoma SurvivorsAmsterdam University Medical Center
- RECRUITINGPHASE2NCT05504291A Study to Give Treatment Inside the Eye to Treat RetinoblastomaChildren's Oncology Group
- RECRUITINGPHASE2, PHASE3NCT04681417Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual OutcomeInstitut Curie